Skip to main content

Table 1 Characteristics at baseline in adolescents with JIA (n = 15) receiving IACs to the TMJs (n = 22)

From: Efficacy and safety of intraarticular corticosteroid injections in adolescents with juvenile idiopathic arthritis in the temporomandibular joint: a Norwegian 2-year prospective multicenter pilot study

Baseline characteristic Value
Female, no. (%) 12 (80)
Age at injections, yrs 15 (11, 16)
Age at JIA onset, yrs. 11 (8, 14)
Disease duration, yrs. 1 (0, 5)
JIA-category, no (%)
 Oligoarthritis persistent 6 (40)
 Polyarthritis RF negative 5 (33)
 Oligoarthritis extended 3 (20)
 Enthesitis related arthritis 1 (7)
Disease activity, no (%)a
 Active 15 (100)
 Remission on medication
 Remission off medication
Medication baseline, no (%)
 No DMARDs 6 (40)
 DMARDs (MTX) 3 (20)
 Biologics combination 6 (40)
Disease activity variables
 JADAS10 baseline (n = 8) 15.8 (12.9, 49.1)
 No.of active joints (n = 14) 2.0 (1.0, 3.0)
 PRpainVAS (n = 10) 4.8 (3.3, 7.6)
 PRgloVAS (n = 10) 5.5 (3.3, 7.1)
 MDgloVAS (n = 12) 2.5 (1.6, 4.5)
 ESR (mm/h) (n = 12) 6.5 (3.5, 10.5)
 TMJ-examination to injection, days 14.0 (1.0, 68.0)
 Follow-up, months 22.0 (16.0, 23.0)
 Injection to 2-months follow-up, (n = 14) 2.0 (1.8, 3.3)
 Injection to 1-year follow-up, months (n = 15) 12.0 (11.0, 13.0)
 Injection to 2-year follow-up, months (n = 11) 22.0 (22.0, 23.0)
 Triamcinolone hexacetonide, dose, mg (n = 14) 20.0 (9.5, 20.0)
 Methylprednisolone acetate, dose, mg (n = 1) 40.0 (n = 1)
 Push-pull technique / No. TMJs (%) 10/22 (46)
 Needle length, mm/ No. TMJs 25 mm/15, 30 mm/7
  1. Data are median (1st, 3rd quartile) unless otherwise indicated. Two patients received repeated injection on the same side, five patients received bilateral injection
  2. IACs intraarticular corticosteroid injection, JIA juvenile idiopathic arthritis, TMJ temporomandibular joint, PRpainVAS patient reported pain visual analogue scale, PRgloVAS patient reported global assessment of well-being, MDgloVAS medical doctor global assessment of well-being, JADAS10 the composite juvenile arthritis10-joint disease activity score, ESR erythrocyte sedimentation rate, MTX methotrexate, DMARDs disease modifying antirheumatic drugs
  3. adisease activity status according to the ACR provisional remission criteria [39]